18 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
16644215	52	Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.	Celera Genomics
16554154	9	Development of activity-based probes for trypsin-family serine proteases.	Celera Genomics
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
12930148	41	Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.	Johnson & Johnson Pharmaceutical Research & Development
16725321	13	Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.	Celera Genomics
15911249	29	Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.	Aventis Pharmaceuticals
15745817	14	Combinatorial approaches towards the discovery of new tryptase inhibitors.	University of Barcelona
15546728	15	Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.	Aventis Pharmaceuticals
15341931	15	Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.	Aventis Pharmaceuticals
11959009	7	Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors.	Institut FüR Biochemie
11527724	30	Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors.	Axys Pharmaceuticals
11055355	72	Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.	Axys Pharmaceuticals
27563406	128	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.	Roche Pharma Research and Early Development
30995036	52	Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.	Novartis Institutes For Biomedical Research